Glaukos Corporation (NYSE:GKOS) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Glaukos Corporation (NYSE:GKOS) have received an average recommendation of “Moderate Buy” from the sixteen analysts that are presently covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell rating, one has assigned a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $132.5385.

A number of research firms have recently commented on GKOS. Truist Financial upped their price target on shares of Glaukos from $120.00 to $145.00 and gave the stock a “buy” rating in a report on Thursday, December 18th. Stifel Nicolaus raised their target price on shares of Glaukos from $115.00 to $160.00 and gave the stock a “buy” rating in a research report on Thursday, January 22nd. JPMorgan Chase & Co. increased their price objective on Glaukos from $110.00 to $120.00 and gave the stock an “overweight” rating in a research note on Thursday, October 30th. William Blair upgraded Glaukos to a “strong-buy” rating in a report on Friday, January 30th. Finally, The Goldman Sachs Group restated a “buy” rating and set a $138.00 price target on shares of Glaukos in a research note on Friday, January 9th.

Glaukos Trading Down 0.2%

Shares of NYSE:GKOS traded down $0.24 during trading hours on Thursday, hitting $114.43. 49,732 shares of the company’s stock traded hands, compared to its average volume of 830,081. Glaukos has a 1 year low of $73.16 and a 1 year high of $161.78. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.20 and a quick ratio of 4.47. The firm has a market capitalization of $6.57 billion, a P/E ratio of -74.40 and a beta of 0.70. The business has a fifty day moving average price of $114.06 and a 200-day moving average price of $97.23.

Insider Buying and Selling

In other news, CEO Thomas William Burns sold 186,945 shares of the company’s stock in a transaction dated Friday, January 16th. The shares were sold at an average price of $115.00, for a total transaction of $21,498,675.00. Following the transaction, the chief executive officer owned 153,775 shares in the company, valued at $17,684,125. This represents a 54.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Marc Stapley sold 15,000 shares of the stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $127.71, for a total value of $1,915,650.00. Following the completion of the transaction, the director directly owned 37,449 shares in the company, valued at $4,782,611.79. This represents a 28.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 329,655 shares of company stock valued at $37,752,234 in the last 90 days. 5.80% of the stock is owned by insiders.

Hedge Funds Weigh In On Glaukos

Large investors have recently bought and sold shares of the business. UMB Bank n.a. increased its position in Glaukos by 102.6% during the third quarter. UMB Bank n.a. now owns 312 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 158 shares during the last quarter. First Horizon Corp raised its position in Glaukos by 1,715.4% in the fourth quarter. First Horizon Corp now owns 236 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 223 shares during the period. REAP Financial Group LLC acquired a new position in shares of Glaukos in the 3rd quarter valued at $40,000. Park Place Capital Corp raised its holdings in Glaukos by 68.4% in the 2nd quarter. Park Place Capital Corp now owns 399 shares of the medical instruments supplier’s stock valued at $41,000 after buying an additional 162 shares during the period. Finally, Farther Finance Advisors LLC boosted its stake in Glaukos by 111.4% during the fourth quarter. Farther Finance Advisors LLC now owns 408 shares of the medical instruments supplier’s stock worth $46,000 after buying an additional 215 shares during the period. Institutional investors and hedge funds own 99.04% of the company’s stock.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.